Company intelligence / Profile preview

Syscore

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

SynCore Biotechnology is developing oncology drugs including SB05PC for metastatic pancreatic cancer resistant to FOLFIRINOX, with FDA-approved new Phase 3 trial expecting to extend survival by up to 13.7 months; previous Phase 3 showed median survival of 226 days vs 209 days in control[1].

Therapeutic areas: OncologyOphthalmologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sinphar Pharmaceutical Co., LtdNational Health Research Institute of Taiwan

Beyond the preview

Go deeper on Syscore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syscore.

Explore the full profile